Skip to content
HowShorted

Sorrento Therapeutics, Inc. short interest in 2022

In 2022, Sorrento Therapeutics, Inc.'s disclosed short interest ran from 13.62% of shares outstanding on 14 Jan 2022 to 13.02% on 30 Dec 2022, a change of -0.60 percentage points. The year's high was 17.49% on 14 Apr 2022 and its low 12.03% on 31 Aug 2022, averaging 14.01% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.33 days on 14 Oct 2022. Full history: Sorrento Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Sorrento Therapeutics, Inc. in 2022

2022 in figures

Start of year
13.62% (14 Jan 2022)
End of year
13.02% (30 Dec 2022)
Change
-0.60 pp
High
17.49% (14 Apr 2022)
Low
12.03% (31 Aug 2022)
Average
14.01%
Highest days to cover
10.33 (14 Oct 2022)
SEC filings marked
5

Every report in 2022

Sorrento Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202213.62%8.78
31 Jan 202215.08%4.44
15 Feb 202214.86%7.03
28 Feb 202215.09%7.66
15 Mar 202214.69%5.2510-K filed
31 Mar 202217.10%4.25
14 Apr 202217.49%6.56results (8-K)
29 Apr 202214.05%5.87
13 May 202213.62%5.0410-Q filed
31 May 202213.90%7.16
15 Jun 202213.36%5.64
30 Jun 202215.45%3.63
15 Jul 202214.65%5.39
29 Jul 202215.48%6.56
15 Aug 202212.25%6.6110-Q filed
31 Aug 202212.03%5.24
15 Sep 202212.56%7.25
30 Sep 202213.04%7.78
14 Oct 202213.48%10.33
31 Oct 202213.36%9.08
15 Nov 202212.27%6.9010-Q filed
30 Nov 202213.14%8.50
15 Dec 202212.57%7.41
30 Dec 202213.02%3.75

See also: Sorrento Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.